TheAnnual Reportstates that about 90% of fiscal 2026 net sales came from proprietary products and about 55% from the aftermarket, most of it commercial and military. Management said commercial aftermarketDemandremains healthy, even with elevated oil prices and passenger traffic below the level forecast when …
Management, led by a chief executive in her 90th day, said U.S. revenue was USD 15.4 million and European revenue was USD 3.6 million. It said the decrease was driven by a USD 2 million decline in OviTex PRS, partly offset by growing international …
Gross profit was USD 11.55 million against USD 10.17 million, which is a gross margin of about 62% against about 59%. Operating expenses were USD 11.0 million against USD 10.8 million. Income from operations was USD 556,000 against a loss of USD 678,000, and …
Management acknowledged growth came in below its own expectation, citing the timing of its commercial organization transition, new account ramp and a faster shift toward super selective Y90 administration in small distal vessels. It said TriNav Advance, which received FDA 510(k) clearance in September …
Total revenue was about USD 13.1 million, compared with USD 15.0 million in the second quarter, a decline of about 13% that management attributed primarily to lower Gram prices, with the number of tokens earned consistent with the prior quarter.
Research and development expense was USD 43.1 million, up USD 17.6 million, driven by a USD 9.1 million increase in external costs for dabogratinib trials and an USD 8.1 million increase in personnel costs from headcount growth. General and administrative expense was USD 11.7 …
Per share figures reflect a 1-for-10Reverse Stock Splitthat occurred on January 22, 2026, which the company applied retroactively to prior periods. Adjusted EBITDA, a non-GAAP measure, was approximately USD 12.3 million against approximately USD 14.2 million.
Net loss for the quarter was USD 41.2 million, compared with USD 33.7 million in the third quarter of 2025. For the nine months, net loss was USD 121.5 million, against USD 101.0 million a year earlier. The accumulatedDeficitstood at USD 455.7 million.
Net income was USD 89.1 million against USD 66.7 million, or USD 0.97 per basic share and USD 0.68 per diluted share against USD 1.21 and USD 0.76. Basic weighted average shares were 91.5 million against 55.3 million.
Total operating expenses were USD 8.21 million against USD 2.84 million, with exploration expenses of USD 7.39 million against USD 2.10 million, general and administrative expenses of USD 0.76 million against USD 0.70 million,Depreciationof USD 57,109 and accretion of USD 5,972.